The Effect of Zinc Supplementation on Expression of Zinc Transporters in Healthy Individuals

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613001200774

Enrollment

Registered

2013-10-31

Start date

2013-10-01

Completion date

2014-03-18

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Sub-groups of the Australian population are considered at risk of zinc deficiency but uncertainty remains in the interpretation of zinc biomarkers. Zinc has no definable, accessible body stores. Our proposal aims to explore the usefulness of zinc transporters, which regulate the movement of zinc into and within-cells, as potential biomarkers of zinc status in humans. We aim to examine the feasibility of using peripheral blood mononuclear cells for the assessment of zinc status. If our approach is successful we will have the potential of investigating zinc status in greater detail.

Interventions

Zinc Chelate 220mg (22mg elemental zinc), one tablet per day for 21 days administered orally (TGA registry - ARTG 128690). Compliance will be checked by tablet return and plasma zinc levels.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

- Adults, age 18-65 y - Have not been diagnosed with major illness

Exclusion criteria

- Diagnosis of major illness - Taking of prescription drugs which known to interact with zinc - Women who are pregnant or breastfeeding

Outcome results